AAM, PhRMA To Continue Battling Over Interchangeability Bill After Markup Delayed

The generic drug lobby plans to continue its push for passage of a bill opposed by brand drug makers that would automatically designate all biosimilar drugs as interchangeable with the reference products after a planned Thursday (Sept. 26) markup of the measure was postponed, the organization confirmed, with Congress’ lame duck period rapidly approaching. The Senate health committee was set to consider the Biosimilar Red Tape Elimination Act Thursday, along with bills on food safety and renewal of FDA’s pediatric...